

09647772

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal613sxw

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

| | | | |
|------|----|--------|--|
| NEWS | 1 | | Web Page URLs for STN Seminar Schedule - N. America |
| NEWS | 2 | | "Ask CAS" for self-help around the clock |
| NEWS | 3 | Feb 24 | PCTGEN now available on STN |
| NEWS | 4 | Feb 24 | TEMA now available on STN |
| NEWS | 5 | Feb 26 | NTIS now allows simultaneous left and right truncation |
| NEWS | 6 | Feb 26 | PCTFULL now contains images |
| NEWS | 7 | Mar 04 | SDI PACKAGE for monthly delivery of multifile SDI results |
| NEWS | 8 | Mar 24 | PATDPAFULL now available on STN |
| NEWS | 9 | Mar 24 | Additional information for trade-named substances without structures available in REGISTRY |
| NEWS | 10 | Apr 11 | Display formats in DGENE enhanced |
| NEWS | 11 | Apr 14 | MEDLINE Reload |
| NEWS | 12 | Apr 17 | Polymer searching in REGISTRY enhanced |
| NEWS | 13 | AUG 22 | Indexing from 1927 to 1936 added to records in CA/CAPLUS |
| NEWS | 14 | Apr 21 | New current-awareness alert (SDI) frequency in WPIDS/WPINDEX/WPIX |
| NEWS | 15 | Apr 28 | RDISCLOSURE now available on STN |
| NEWS | 16 | May 05 | Pharmacokinetic information and systematic chemical names added to PHAR |
| NEWS | 17 | May 15 | MEDLINE file segment of TOXCENTER reloaded |
| NEWS | 18 | May 15 | Supporter information for ENCOMPPAT and ENCOMPLIT updated |
| NEWS | 19 | May 19 | Simultaneous left and right truncation added to WSCA |
| NEWS | 20 | May 19 | RAPRA enhanced with new search field, simultaneous left and right truncation |
| NEWS | 21 | Jun 06 | Simultaneous left and right truncation added to CBNB |
| NEWS | 22 | Jun 06 | PASCAL enhanced with additional data |
| NEWS | 23 | Jun 20 | 2003 edition of the FSTA Thesaurus is now available |
| NEWS | 24 | Jun 25 | HSDB has been reloaded |
| NEWS | 25 | Jul 16 | Data from 1960-1976 added to RDISCLOSURE |
| NEWS | 26 | Jul 21 | Identification of STN records implemented |
| NEWS | 27 | Jul 21 | Polymer class term count added to REGISTRY |
| NEWS | 28 | Jul 22 | INPADOC: Basic index (/BI) enhanced; Simultaneous Left and Right Truncation available |
| NEWS | 29 | AUG 05 | New pricing for EUROPATFULL and PCTFULL effective August 1, 2003 |
| NEWS | 30 | AUG 13 | Field Availability (/FA) field enhanced in BEILSTEIN |
| NEWS | 31 | AUG 15 | PATDPAFULL: one FREE connect hour, per account, in September 2003 |
| NEWS | 32 | AUG 15 | PCTGEN: one FREE connect hour, per account, in September 2003 |
| NEWS | 33 | AUG 15 | RDISCLOSURE: one FREE connect hour, per account, in September 2003 |
| NEWS | 34 | AUG 15 | TEMA: one FREE connect hour, per account, in |

09647772

September 2003
NEWS 35 AUG 18 Data available for download as a PDF in RDISCLOSURE
NEWS 36 AUG 18 Simultaneous left and right truncation added to PASCAL
NEWS 37 AUG 18 FROSTI and KOSMET enhanced with Simultaneous Left and Right
Truncation
NEWS 38 AUG 18 Simultaneous left and right truncation added to ANABSTR

NEWS EXPRESS April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT
MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 13:55:24 ON 05 SEP 2003

=> fil reg

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|----------------------|---------------------|------------------|
| FULL ESTIMATED COST | 0.21 | 0.21 |

FILE 'REGISTRY' ENTERED AT 13:55:29 ON 05 SEP 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 4 SEP 2003 HIGHEST RN 579436-73-0
DICTIONARY FILE UPDATES: 4 SEP 2003 HIGHEST RN 579436-73-0

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP
PROPERTIES for more information. See STNote 27, Searching Properties
in the CAS Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=>

Uploading 09647772.str


09647772

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 13:55:58 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 354 TO ITERATE

100.0% PROCESSED 354 ITERATIONS

2 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 5952 TO 8208

PROJECTED ANSWERS: 2 TO 124

L2 2 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 13:56:09 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 7051 TO ITERATE

100.0% PROCESSED 7051 ITERATIONS

52 ANSWERS

SEARCH TIME: 00.00.01

L3 52 SEA SSS FUL L1

=> fil caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

148.15

148.36

FILE 'CAPLUS' ENTERED AT 13:56:18 ON 05 SEP 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available

09647772

for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 5 Sep 2003 VOL 139 ISS 11
FILE LAST UPDATED: 4 Sep 2003 (20030904/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3 full



L4 3 L3

=> d l4 1-3 ibib abs hitstr

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:483072 CAPLUS
DOCUMENT NUMBER: 137:47109
TITLE: Preparation of trisubstituted indole derivatives for inhibiting neoplastic cells
INVENTOR(S): Pamukcu, Rifat; Piazza, Gary A.
PATENT ASSIGNEE(S): Cell Pathways, Inc., USA
SOURCE: U.S., 76 pp., Cont.-in-part of U. S. 6,046,199.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------------------|------|------------------|-----------------|-------------|
| US 6410584 | B1 | 20020625 | US 1998-199860 | 19981125 |
| US 6046199 | A | 20000404 | US 1998-7098 | 19980114 |
| US 2002143022 | A1 | 20021003 | US 2002-71639 | 20020207 |
| PRIORITY APPLN. INFO.: | | | US 1998-7098 | A2 19980114 |
| | | | US 1998-199860 | A3 19981125 |
| OTHER SOURCE(S): | | MARPAT 137:47109 | | |

GI



AB Title compds. I [R1-3 = H, alkyl, alkylthio alkoxy, with the proviso that

R1-3 are not simultaneously hydrogen atoms; R4 = H, alkyl; R5 = carboxy, an esterified carboxy group, or an amidated carboxy group] were prepd. For instance, 6-methoxycarbonyl-2-methylindole was N-alkylated with 2-chlorobenzyl bromide (DMF, K₂CO₃, 80.degree.C, 18 h); the product sapond. and the resulting acid coupled to benzenesulfonamide (DMF, CDI, DBU) to afford II. I are used for inhibiting the growth of neoplastic cells (no data).

IT **206065-16-9P**, 5-((Benzenesulfonyl)carbamoyl)-3-(2,4-dichlorobenzyl)-2-methylindole **206065-31-8P**, 3-(2,4-Dichlorobenzyl)-5-[[[(4-methoxybenzene)sulfonyl]carbamoyl]-2-methylindole **206065-32-9P**, 5-(((Benzenesulfonyl)carbamoyl))-3-(2,4-dichlorobenzyl)-2-ethylindole **206065-43-2P**, 5-((Cyclohexane)sulfonyl)carbamoyl)-3-(2,4-dichlorobenzyl)-2-methylindole **206065-53-4P**, 3-(2,4-Dichlorobenzyl)-2-methyl-5-[[[(4-methylbenzene)sulfonyl]carbamoyl]indole **206065-55-6P**, 3-(2,4-Dichlorobenzyl)-2-methyl-5-[[[(4-nitrobenzene)sulfonyl]carbamoyl]indole **206065-57-8P**, 5-[[[(4-Chlorobenzene)sulfonyl]carbamoyl]-3-(2,4-dichlorobenzyl)-2-methylindole **206065-59-0P**, 5-[[[(3-Chlorobenzene)sulfonyl]carbamoyl]-3-(2,4-dichlorobenzyl)-2-methylindole **206065-61-4P**, 5-[[[(2-Chlorobenzene)sulfonyl]carbamoyl]-3-(2,4-dichlorobenzyl)-2-methylindole **206065-63-6P**, 3-(2,4-Dichlorobenzyl)-5-[[[(4-fluorobenzene)sulfonyl]carbamoyl]-2-methylindole **206065-64-7P**, 3-(2,4-Dichlorobenzyl)-2-methyl-5-[[[(2-naphthalene)sulfonyl]carbamoyl]indole **206065-65-8P**, 3-(2,4-Dichlorobenzyl)-2-methyl-5-[[[naphthalen-1-yl)sulfonyl]carbamoyl]indole **206065-66-9P**, 3-(2,4-Dichlorobenzyl)-2-methyl-5-[[[(2-methylbenzene)sulfonyl]carbamoyl]indole **206065-68-1P**, 5-(((4-Bromobenzene)sulfonyl)carbamoyl)-3-(2,4-dichlorobenzyl)-2-methylindole **206065-70-5P**, 3-(2,4-Dichlorobenzyl)-2-methyl-5-[[[(4-vinylbenzene)sulfonyl]carbamoyl]indole **206065-71-6P**, 5-[[[(4-(Phenylazo)benzene)sulfonyl]carbamoyl]-3-(2,4-dichlorobenzyl)-2-methylindole **206065-72-7P**, 3-(2,4-Dichlorobenzyl)-2-methyl-5-[[[(4-trifluoromethylbenzene)sulfonyl]carbamoyl]indole **206065-74-9P**, 3-(2,4-Dichlorobenzyl)-5-[[[(3,4-dimethoxybenzene)sulfonyl]carbamoyl]-2-methylindole **206065-76-1P**, 5-[[[(4-tert-Butylbenzene)sulfonyl]carbamoyl]-3-(2,4-dichlorobenzyl)-2-methylindole **206065-77-2P**, 3-(2,4-Dichlorobenzyl)-2-methyl-5-[[[(3-methylbenzene)sulfonyl]carbamoyl]indole **206065-81-8P**, 3-(2,4-Dichlorobenzyl)-2-methyl-5-[[[(4-phenylbenzene)sulfonyl]carbamoyl]indole **206065-83-0P**, 5-((Benzenesulfonyl)carbamoyl)-3-[2-chloro-4-phenylbenzyl]-2-methylindole **206065-85-2P**, 5-[[[(4-n-Butylbenzene)sulfonyl]carbamoyl]-3-(2,4-dichlorobenzyl)-2-methylindole **206065-86-3P**, 5-[[[(4-(Butoxy)benzene)sulfonyl]carbamoyl]-3-(2,4-dichlorobenzyl)-2-methylindole **206065-96-5P**, 3-[(1-Bromonaphthalen-2-yl)methyl]-2-methyl-5-[[[(4-vinylbenzene)sulfonyl]carbamoyl]indole **206065-98-7P**, 5-[[[Benzenesulfonyl]carbamoyl]-3-[(1-bromonaphthalen-2-yl)methyl]-2-methylindole **206066-00-4P**, 3-[2-Chloro-4-phenylbenzyl]-2-methyl-5-[[[(4-vinylbenzene)sulfonyl]carbamoyl]indole **206066-02-6P**, 3-[2-Chloro-4-phenylbenzyl]-2-methyl-5-[[[4-methylphenylsulfonyl]carbamoyl]indole **438003-21-5P**, 3-(2,4-Dichlorobenzyl)-5-(((2,5-dimethylbenzene)sulfonyl)carbamoyl)-2-methylindole **438003-26-0P**, 3-(2,4-Dichlorobenzyl)-5-[[[(4-ethylbenzene)sulfonyl]carbamoyl]-2-methylindole **438003-36-2P**, 3-[(1-Bromonaphthalen-2-yl)methyl]-2-methyl-5-[[[p-toluenesulfonyl]carbamoyl]indole

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(drug; prepn. of trisubstituted indole derivs. for inhibiting

09647772

neoplastic cells)


RN 206065-16-9 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 206065-31-8 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-N-[(4-methoxyphenyl)sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 206065-32-9 CAPLUS


CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-ethyl-N-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



RN 206065-43-2 CAPLUS


CN 1H-Indole-5-carboxamide, N-(cyclohexylsulfonyl)-3-[(2,4-dichlorophenyl)methyl]-2-methyl- (9CI) (CA INDEX NAME)

09647772




RN 206065-53-4 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 206065-55-6 CAPLUS


CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-[(4-nitrophenyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 206065-57-8 CAPLUS


CN 1H-Indole-5-carboxamide, N-[(4-chlorophenyl)sulfonyl]-3-[(2,4-dichlorophenyl)methyl]-2-methyl- (9CI) (CA INDEX NAME)

09647772




RN 206065-59-0 CAPLUS

CN 1H-Indole-5-carboxamide, N-[(3-chlorophenyl)sulfonyl]-3-[(2,4-dichlorophenyl)methyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 206065-61-4 CAPLUS


CN 1H-Indole-5-carboxamide, N-[(2-chlorophenyl)sulfonyl]-3-[(2,4-dichlorophenyl)methyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 206065-63-6 CAPLUS


CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-N-[(4-fluorophenyl)sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)

09647772




RN 206065-64-7 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-(2-naphthalenylsulfonyl)- (9CI) (CA INDEX NAME)



RN 206065-65-8 CAPLUS


CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-(1-naphthalenylsulfonyl)- (9CI) (CA INDEX NAME)



RN 206065-66-9 CAPLUS


CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-[(2-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)

09647772




RN 206065-68-1 CAPLUS

CN 1H-Indole-5-carboxamide, N-[(4-bromophenyl)sulfonyl]-3-[(2,4-dichlorophenyl)methyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 206065-70-5 CAPLUS


CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-N-[(4-ethenylphenyl)sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 206065-71-6 CAPLUS


CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-[[4-(phenylazo)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)

09647772




RN 206065-72-7 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-[[4-(trifluoromethyl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 206065-74-9 CAPLUS


CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-N-[(3,4-dimethoxyphenyl)sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 206065-76-1 CAPLUS


CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-N-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)

09647772




RN 206065-77-2 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-[(3-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 206065-81-8 CAPLUS


CN 1H-Indole-5-carboxamide, N-([1,1'-biphenyl]-4-ylsulfonyl)-3-[(2,4-dichlorophenyl)methyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-83-0 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(3-chloro[1,1'-biphenyl]-4-yl)methyl]-2-methyl-N-(phenylsulfonyl)- (9CI) (CA INDEX NAME)


09647772




RN 206065-85-2 CAPLUS
CN 1H-Indole-5-carboxamide, N-[(4-butylphenyl)sulfonyl]-3-[(2,4-dichlorophenyl)methyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 206065-86-3 CAPLUS
CN 1H-Indole-5-carboxamide, N-[(4-butoxyphenyl)sulfonyl]-3-[(2,4-dichlorophenyl)methyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-96-5 CAPLUS
CN 1H-Indole-5-carboxamide, 3-[(1-bromo-2-naphthalenyl)methyl]-N-[(4-ethenylphenyl)sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)




09647772


RN 206065-98-7 CAPLUS
CN 1H-Indole-5-carboxamide, 3-[(1-bromo-2-naphthalenyl)methyl]-2-methyl-N-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



RN 206066-00-4 CAPLUS
CN 1H-Indole-5-carboxamide, 3-[(3-chloro[1,1'-biphenyl]-4-yl)methyl]-N-[(4-ethenylphenyl)sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206066-02-6 CAPLUS
CN 1H-Indole-5-carboxamide, 3-[(3-chloro[1,1'-biphenyl]-4-yl)methyl]-2-methyl-N-[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 438003-21-5 CAPLUS
CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-N-[(2,5-dimethylphenyl)sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)

09647772




RN 438003-26-0 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-N-[(4-ethylphenyl)sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 438003-36-2 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(1-bromo-2-naphthalenyl)methyl]-2-methyl-N-[(2-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1999:659360 CAPLUS

DOCUMENT NUMBER: 131:271808

TITLE: Preparation of indole derivatives as PDE5 inhibitors

INVENTOR(S): Yamasaki, Noritsugu; Imoto, Takafumi; Oku, Teruo; Kayakiri, Hiroshi; Onomura, Osamu; Hiramura, Takahiro


PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 88 pp.

09647772

DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|-------------------|------------|
| WO 9951574 | A1 | 19991014 | WO 1999-JP1798 | 19990405 |
| W: BR, CA, CN, JP, KR, US | | | | |
| RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE | | | | |
| CA 2327397 | AA | 19991014 | CA 1999-2327397 | 19990405 |
| BR 9909440 | A | 20001226 | BR 1999-9440 | 19990405 |
| EP 1070705 | A1 | 20010124 | EP 1999-912110 | 19990405 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI | | | | |
| PRIORITY APPLN. INFO.: | | | JP 1998-93625 | A 19980406 |
| | | | WO 1999-JP1798 | W 19990405 |
| OTHER SOURCE(S): | | | MARPAT 131:271808 | |
| GI | | | | |



AB Title compds. [I; or salts thereof, wherein R1 is aryl-substituted lower alkyl in which the aryl may be substituted by at least one member selected among halogen atoms, aryls, heterocyclic groups, aryl-substituted lower alkyls, aryl-substituted lower alkenyls, lower haloalkyls, (lower cycloalkyl)-substituted lower alkyloxys, (lower cycloalkyloxy)-substituted lower alkyls, aryl-substituted lower alkynyls, aryloxy-substituted lower alkyls, aryl-substituted lower alkyloxys, lower alkylthios, lower alkyloxys, and alkenyls; and R2 is a lower alkyl, lower alkenyl, aryl, or heterocyclic group optionally substituted by halogeno, lower alkyl, lower alkenyl, or aryl] are prepd. having hypoglycemic activity and a PDE5 inhibitory activity and are useful as agents on treatment of diabetes and on set diseases caused by diabetes. Thus, the title compd. I (R1 = 2-Cl-4-BrC6H3CH2; R2 = CH2:CH(CH2)3CH2) was prepd.


IT 245367-80-0P 245367-82-2P 245367-84-4P
245367-85-5P 245367-87-7P 245367-88-8P
245367-89-9P 245367-95-7P 245367-96-8P
245368-04-1P 245368-07-4P 245368-11-0P
245368-13-2P 245368-14-3P 245368-16-5P
245368-19-8P 245368-20-1P 245368-52-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of indole derivs. as PDE5 inhibitors)

RN 245367-80-0 CAPLUS


09647772

CN 1H-Indole-5-carboxamide, 3-[[2-chloro-4-[(1,1-dimethylethyl)thio]phenyl]methyl]-2-methyl-N-[(4-methylphenyl)sulfonyl]-
(9CI) (CA INDEX NAME)




RN 245367-82-2 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[[2-chloro-4-iodophenyl]methyl]-2-methyl-N-[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 245367-84-4 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[[2-chloro-4-(phenylethynyl)phenyl]methyl]-2-methyl-N-[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 245367-85-5 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[[2-chloro-4-(2-phenylethenyl)phenyl]methyl]-2-


09647772

methyl-N-[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 245367-87-7 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[[2-chloro-4-(2-phenylethyl)phenyl]methyl]-2-methyl-N-[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 245367-88-8 CAPLUS


CN 1H-Indole-5-carboxamide, 3-[[2-chloro-4-(phenylmethoxy)phenyl]methyl]-2-methyl-N-[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 245367-89-9 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[[2-chloro-4-(cyclohexylmethoxy)phenyl]methyl]-2-methyl-N-[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)


09647772



RN 245367-95-7 CAPLUS
CN 1H-Indole-5-carboxamide, 3-[(4-bromo-2-chlorophenyl)methyl]-2-methyl-N-[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 245367-96-8 CAPLUS
CN 1H-Indole-5-carboxamide, 3-[(4-bromo-2-chlorophenyl)methyl]-N-[(4-ethenylphenyl)sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 245368-04-1 CAPLUS
CN 1H-Indole-5-carboxamide, 3-[[2-chloro-4-(trifluoromethyl)phenyl]methyl]-2-methyl-N-[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)

09647772




RN 245368-07-4 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[[2-chloro-4-(trifluoromethyl)phenyl]methyl]-N-[(4-ethenylphenyl)sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 245368-11-0 CAPLUS


CN 1H-Indole-5-carboxamide, 3-[[2-chloro-4-(phenoxymethyl)phenyl]methyl]-2-methyl-N-[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 245368-13-2 CAPLUS


CN 1H-Indole-5-carboxamide, 3-[[2-chloro-4-[(cyclohexyloxy)methyl]phenyl]methyl]-2-methyl-N-[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)

09647772




RN 245368-14-3 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2-chloro-4-ethoxyphenyl)methyl]-2-methyl-N-[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)




09647772

N-[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 245368-52-9 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[[2-chloro-4-(1-methylenepentyl)phenyl]methyl]-2-methyl-N-[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1998:239201 CAPLUS

DOCUMENT NUMBER: 128:294695

TITLE: Preparation and formulation of indole derivatives as hypoglycemics and phosphodiesterase 5 inhibitors

INVENTOR(S): Yamasaki, Noritsugu; Imoto, Takafumi; Murai, Yoshiyuki; Hiramura, Takahiro; Onomura, Osamu; Nishikawa, Masahiro; Oku, Teruo; Sawada, Kouzou; Kayakiri, Hiroshi; et al.

PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan; Yamasaki, Noritsugu; Imoto, Takafumi; Murai, Yoshiyuki; Hiramura, Takahiro; Onomura, Osamu; Nishikawa, Masahiro; Oku, Teruo; Sawada, Kouzou; Kayakiri, Hiroshi

SOURCE: PCT Int. Appl., 184 pp.

CODEN: PIXXD2



DOCUMENT TYPE: Patent

LANGUAGE: Japanese

09647772

FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-------------------|------------|
| WO 9815530 | A1 | 19980416 | WO 1997-JP3592 | 19971007 |
| W: AU, BR, CA, CN, HU, IL, JP, KR, MX, NZ, RU, SG, TR, US, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, NL, PT, SE | | | | |
| AU 9744005 | A1 | 19980505 | AU 1997-44005 | 19971007 |
| ZA 9708998 | A | 19980420 | ZA 1997-8998 | 19971008 |
| PRIORITY APPLN. INFO.: | | | JP 1996-287676 | A 19961008 |
| | | | JP 1997-187536 | A 19970627 |
| | | | WO 1997-JP3592 | W 19971007 |
| OTHER SOURCE(S): | | | MARPAT 128:294695 | |
| GI | | | | |



AB The title compds. I [R1 - R3 = H, alkyl, etc.; a proviso is given; R4 = H, alkyl; R5 = carboxy, etc.] are prepd. I are useful as remedies for impaired glucose tolerance, diabetes, complication of diabetes, insulin resistant syndrome, hyperlipidemia, atherosclerosis, cardiovascular diseases, hyperglycemia, hypertension; diseases characterized by angina pectoris, high blood pressure, pulmonary hypertension, congestive heart failure, glomerular diseases, tubular interstitial diseases, renal insufficiency, atherosclerosis, angiostenosis, peripheral vascular diseases, cerebral stroke, chronic reversible obstructive diseases, allergic rhinitis, urticaria, glaucoma or intestinal motility disorders; sexual impotence, osteoporosis, nephritis, cancerous cachexia or post-PTCA reconstruction. The title compd. II at 10 mg/kg gave 46% decrease of blood sugar in mice.

IT 206065-16-9P 206065-31-8P 206065-32-9P
206065-43-2P 206065-53-4P 206065-55-6P
206065-57-8P 206065-59-0P 206065-61-4P


09647772

206065-63-6P 206065-64-7P 206065-65-8P
206065-66-9P 206065-67-0P 206065-68-1P
206065-70-5P 206065-71-6P 206065-72-7P
206065-74-9P 206065-76-1P 206065-77-2P
206065-81-8P 206065-83-0P 206065-84-1P
206065-85-2P 206065-86-3P 206065-96-5P
206065-97-6P 206065-98-7P 206066-00-4P
206066-02-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of indole derivs. as hypoglycemics and phosphodiesterase 5 inhibitors)


RN 206065-16-9 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 206065-31-8 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-N-[(4-methoxyphenyl)sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 206065-32-9 CAPLUS


CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-ethyl-N-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



09647772


RN 206065-43-2 CAPLUS

CN 1H-Indole-5-carboxamide, N-(cyclohexylsulfonyl)-3-[(2,4-dichlorophenyl)methyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-53-4 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 206065-55-6 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-[(4-nitrophenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 206065-57-8 CAPLUS

CN 1H-Indole-5-carboxamide, N-[(4-chlorophenyl)sulfonyl]-3-[(2,4-


09647772

dichlorophenyl)methyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-59-0 CAPLUS

CN 1H-Indole-5-carboxamide, N-[(3-chlorophenyl)sulfonyl]-3-[(2,4-dichlorophenyl)methyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 206065-61-4 CAPLUS


CN 1H-Indole-5-carboxamide, N-[(2-chlorophenyl)sulfonyl]-3-[(2,4-dichlorophenyl)methyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 206065-63-6 CAPLUS


CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-N-[(4-fluorophenyl)sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)

09647772




RN 206065-64-7 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-(2-naphthalenylsulfonyl)- (9CI) (CA INDEX NAME)



RN 206065-65-8 CAPLUS


CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-(1-naphthalenylsulfonyl)- (9CI) (CA INDEX NAME)



RN 206065-66-9 CAPLUS


CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-[(2-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)

09647772




RN 206065-67-0 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-N-[(2,6-dimethylphenyl)sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 206065-68-1 CAPLUS


CN 1H-Indole-5-carboxamide, N-[(4-bromophenyl)sulfonyl]-3-[(2,4-dichlorophenyl)methyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 206065-70-5 CAPLUS


CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-N-[(4-ethenylphenyl)sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)

09647772




RN 206065-71-6 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-[[4-(phenylazo)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 206065-72-7 CAPLUS


CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-[[4-(trifluoromethyl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 206065-74-9 CAPLUS


CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-N-[(3,4-dimethoxyphenyl)sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)

09647772




RN 206065-76-1 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-N-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 206065-77-2 CAPLUS


CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-[(3-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 206065-81-8 CAPLUS


CN 1H-Indole-5-carboxamide, N-([1,1'-biphenyl]-4-ylsulfonyl)-3-[(2,4-dichlorophenyl)methyl]-2-methyl- (9CI) (CA INDEX NAME)

09647772




RN 206065-83-0 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(3-chloro[1,1'-biphenyl]-4-yl)methyl]-2-methyl-N-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



RN 206065-84-1 CAPLUS


CN 1H-Indole-5-carboxamide, 3-[(3-chloro[1,1'-biphenyl]-4-yl)methyl]-N-[(4-ethylphenyl)sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 206065-85-2 CAPLUS


CN 1H-Indole-5-carboxamide, N-[(4-butylphenyl)sulfonyl]-3-[(2,4-dichlorophenyl)methyl]-2-methyl- (9CI) (CA INDEX NAME)

09647772




RN 206065-86-3 CAPLUS

CN 1H-Indole-5-carboxamide, N-[(4-butoxyphenyl)sulfonyl]-3-[(2,4-dichlorophenyl)methyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-96-5 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(1-bromo-2-naphthalenyl)methyl]-N-[(4-ethenylphenyl)sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 206065-97-6 CAPLUS


CN 1H-Indole-5-carboxamide, 3-[(1-bromo-2-naphthalenyl)methyl]-2-methyl-N-[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)



09647772


RN 206065-98-7 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(1-bromo-2-naphthalenyl)methyl]-2-methyl-N-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 206066-00-4 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(3-chloro[1,1'-biphenyl]-4-yl)methyl]-N-[(4-ethenylphenyl)sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 206066-02-6 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(3-chloro[1,1'-biphenyl]-4-yl)methyl]-2-methyl-N-[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

53

THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT